BioNexus Gene Lab Corp
Close on Oct 19, 2026
- Market cap
- $2.97M
- P/E (TTM)
- –
- Dividend yield
- –
About BioNexus Gene Lab
Services-Medical Laboratories, SIC 8071
BioNexus Gene Lab Corp. operates in chemical raw material distribution and genomic testing through its operating subsidiaries. The company wholesales chemical raw materials, primarily fiber-reinforced polymers and polyester resins, serving manufacturers, fabricators, and contractors across the industrial, automotive, aerospace, medical, appliance, and electronic sectors. It also provides blood-based genomic screening services and laboratory analysis that assess ribonucleic acid changes to evaluate risk for cancers, inflammatory bowel diseases, osteoarthritis, and cardiovascular conditions, delivering risk analysis reports to referring doctors, clinics, and hospitals.
The company maintains operational activities in Southeast Asia, selling chemical raw materials to clients in Malaysia, Indonesia, and Vietnam. Its physical footprint in Malaysia includes a corporate office in Kuala Lumpur, two diagnostic screening laboratories situated in Kuala Lumpur and Penang, a wholesale distribution center and two investment properties in Selangor, and an industrial lease in Selangor. Principal executive offices are located in Kuala Lumpur, Malaysia.
Summary of the business section of BioNexus Gene Lab's latest annual report, written by StockData.
Company profile
Company
- Legal name
- BioNexus Gene Lab Corp
- Founded
- 2017
- Headquarters
- Kuala Lumpur, Malaysia
- Address
- Unit A-28-7, Tower A, Menara Uoa Bangsar, No. 5 Jln Bangsar Utama 1 59000
- Phone
- 1-307-241-6898
- Website
- bionexusgenelab.com
- Employees
- 6, Dec 31, 2025
- Industry
- Services-Medical Laboratories
- Incorporated in
- WY
- Fiscal year ends
- December 31
- Auditor
- JP CENTURION & PARTNERS PLT, Kuala Lumpur, Malaysia
Stock & identifiers
- Ticker
- BGLC
- Exchange
- Nasdaq
- Shares outstanding
- 3M, Aug 14, 2026
- Public float
- $4.81M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Apr 7, 2025
- SEC CIK
- 1737523
- CUSIP
- 090628306
- ISIN
- US0906283066
- LEI
- 549300COYSKRA3Z7E531
- EIN
- 26-2124961
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lee Su-Leng Tan | Chief Executive Officer, Director | 338,709 |
| Set Fui Chong | Chief Financial Officer | 96,774 |
| Jook Yuen Low | Director | 17,390 |
| Abdul Hamid Muhammad Azrul Bin | Director | 32,258 |
| Chee Keong Yap | Director | 32,258 |
Employees
Headcount reported in annual reports
“As of date of this filing, Chemrex has 6 full-time employees, and MRNA Scientific has 10 full time employees.”
Corporate history
Events identified from SEC filings